Novo mecanismo de crescimento independente de hormonas no cancro da mama luminal

envie a um amigo share this

Novo mecanismo de crescimento independente de hormonas no cancro da mama luminal

Terça, 10.09.2019

A resistência do cancro da mama à terapia endócrina caracteriza-se pela capacidade dos tumores, mesmo que positivos para recetores hormonais, continuem a progredir sem intervenção hormonal. Como tal, este trabalho teve como objetivo estudar a regulação da atividade transcricional dos recetores hormonais quando estimulados pelo fator de crescimento de fibroblastos (FGF2) e as suas implicações para o desenvolvimento da resistência à terapia hormonal. O FGF2 estimula a ativação transcricional dos oncogenes MYC e CCND1 mediada pela interação dos recetores de estrogénio e progesterona. Uma análise de espetrometria de massa identificou o complexo transcricional que regula a expressão do MYC e CCND1 que incorpora uma nova isoforma do recetor de progesterona, a PR delta 4, que não contém o domínio de união à hormona. Esta descoberta explica o crescimento independente de hormonas, a falta de resposta à terapia hormonal e salienta a relevância de estudar as isoformas não canónicas dos recetores hormonais para avaliar a resposta à terapia.


Giulianelli S (1,2), Riggio M (1), Guillardoy T (1), Pérez Piñero C (1), Gorostiaga MA (1), Sequeira G (1), Pataccini G (1), Abascal MF (1), Toledo MF (1), Jacobsen BM (3), Guerreiro AC (4), Barros A (4), Novaro V (1), Monteiro FL (5), Amado F (4), Gass H (6), Abba M (7), Helguero LA* (5), Lanari C* (1). * co-senior authors

(1) Instituto de Biología y Medicina Experimental, IByME-CONICET, Buenos Aires, Argentina.

(2) Instituto de Biología de Organismos Marinos, IBIOMAR-CCT CENPAT-CONICET, Puerto Madryn, Argentina.

(3) Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

(4) Department of Chemistry, QOPNA - Universidade de Aveiro, Aveiro, Portugal.

(5) Department of Medical Sciences, iBiMED - Universidade de Aveiro, Aveiro, Portugal.

(6) Hospital de Agudos Magdalena V de Martínez, General Pacheco, Buenos Aires, Argentina.

(7) CINIBA, Universidad Nacional de La Plata, La Plata, Argentina.

Progression to hormone-independent growth leading to endocrine therapy resistance occurs in a high proportion of patients with estrogen receptor alpha (ERα) and progesterone receptors (PR) positive breast cancer. We and others have previously shown that estrogen- and progestin-induced tumor growth requires ERα and PR interaction at their target genes. Here, we show that fibroblast growth factor 2 (FGF2)-induces cell proliferation and tumor growth through hormone-independent ERα and PR activation and their interaction at the MYC enhancer and proximal promoter. MYC inhibitors, antiestrogens or antiprogestins reverted FGF2-induced effects. LC-MS/MS identified 700 canonical proteins recruited to MYC regulatory sequences after FGF2 stimulation, 397 of which required active ERα (ERα-dependent). We identified ERα-dependent proteins regulating transcription that, after FGF2 treatment, were recruited to the enhancer as well as proteins involved in transcription initiation that were recruited to the proximal promoter. Also, among the ERα-dependent and independent proteins detected at both sites, PR isoforms A and B as well as the novel protein product Descoberta de um novo mecanismo de crescimento independente de hormonas no cancrPRBΔ4 were found. PRBΔ4 lacks the hormone-binding domain and was able to induce reporter gene expression from estrogen-regulated elements and to increase cell proliferation when cells were stimulated with FGF2 but not by progestins. Analysis of the Cancer Genome Atlas data set revealed that PRBΔ4 expression is associated with worse overall survival in luminal breast cancer patients. This discovery provides a new mechanism by which growth factor signaling can engage nonclassical hormone receptor isoforms such as PRBΔ4, which interacts with growth-factor activated ERα and PR to stimulate MYC gene expression and hence progression to endocrine resistance.

Int J Cancer. 2019 Oct 1;145(7):1874-1888. doi: 10.1002/ijc.32252. Epub 2019 Mar 28.

https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.32252